Journal Report

Hematological Oncology

Download PDF
Journal Information
Journal Title
Hematological Oncology
Publisher
John Wiley and Sons Ltd
ISSN
0278-0232
E-ISSN
1099-1069
Database
SCOPUS
Domain
Health Sciences, Life Sciences, Physical Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Temporal Trends in Real‐World Outcomes With CPX‐351 in Secondary/High‐Risk Acute Myeloid Leukemia: A PETHEMA Study
Josefina Serrano, Alicia Aguirre, David Martínez‐Cuadrón et al.
2026-11 Vol. 44 Issue 6
DOI: 10.1002/hon.70288
Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non‐Erythroid Blood Counts
Mara Memoli, Stefania Leone, Vincenzo Fotticchia et al.
2026-11 Vol. 44 Issue 6
DOI: 10.1002/hon.70281
The Histone Lactylation of KREMEN2 Inhibits Ferroptosis Through the JAK2/STAT3/GPX4 Axis and Promotes the Progression of Mantle Cell Lymphoma
Shujun Li, Jingmin Luo, Wenjia Wei et al.
2026-11 Vol. 44 Issue 6
DOI: 10.1002/hon.70285
Baseline Spleen Volume is Independently Associated With Survival After CD19‐Directed Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
Lucas Brehm, Philipp Schindler, Christian Römer et al.
2026-11 Vol. 44 Issue 6
DOI: 10.1002/hon.70284
Therapeutic Approaches and Clinical Outcomes of Myeloid/Lymphoid Neoplasms With Eosinophilia Harboring <i>FLT3</i> Rearrangements: A Systematic Review of 39 Cases
Peng Fang, Peng Zhang, Fan Yang et al.
2026-11 Vol. 44 Issue 6
DOI: 10.1002/hon.70283
Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy
Paolo Sportoletti, Felice Bombaci, Chiara Cernetti et al.
2026-11 Vol. 44 Issue 6
DOI: 10.1002/hon.70274
Macular OCTA Biomarkers of Ocular Involvement in Patients With Primary Central Nervous System Lymphoma
Tianyu Zhu, Qingjian Li, Yuanyuan Zhang et al.
2026-10-30 Vol. 44 Issue 6
DOI: 10.1002/hon.70289
Navigating Measurable Residual Disease as a Surrogate Endpoint in Chronic Lymphocytic Leukemia
Stefano Molica
2026-10-27 Vol. 44 Issue 6
DOI: 10.1002/hon.70287
Baseline Monoclonal Protein Identifies Plasmacytic Differentiation and Shorter Progression‐Free Survival in Marginal Zone Lymphoma
Wei Wang, Danqing Zhao, Chen Yang et al.
2026-10-27 Vol. 44 Issue 6
DOI: 10.1002/hon.70286
Adjusted Indirect Comparison Between Epcoritamab‐R <sup>2</sup> and Tafasitamab‐R <sup>2</sup> in Relapse/Refractory Follicular Lymphoma
Leonidas Benetatos, Elisavet Apostolidou, Vasileios Georgoulis et al.
2026-10-24 Vol. 44 Issue 6
DOI: 10.1002/hon.70282
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 9, 2026 04:35